G1 Therapeutics, Inc.

Ownership Transactions Reported by 18 Insiders

Symbol
GTHX on Nasdaq
Industry
Pharmaceutical Preparations
Location
700 Park Offices Drive, Suite 200, Research Triangle Park, NC

Insiders trading volume in the past year

G1 Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Mark A. Velleca Director $341K Aug 8, 2023
Jennifer K. Moses Cfo $170K Jan 3, 2023
James S. Hanson General Counsel $121K Jan 3, 2023
Willie A. Deese Director $42.3K Jun 23, 2022
Seth Rudnick Director $28.4K Jun 29, 2021
Jacks Lee Director $0 Sep 18, 2024
Glenn P. Muir Director $0 Sep 18, 2024
Rajesh Malik Chief Medical Officer $0 -$304K -100% Sep 18, 2024
Garry A. Nicholson Director $0 Sep 18, 2024
Andrew Perry Chief Commercial Officer $0 -$49.9K -100% Sep 18, 2024
John E. Bailey President and CEO, Director $0 -$342K -100% Sep 18, 2024
Mark Avagliano Chief Business Officer $0 -$58.3K -100% Sep 18, 2024
Monica Thomas Chief Legal & People Officer $0 -$24.9K -100% Sep 18, 2024
Terry L. Murdock Chief Operating Officer $0 -$56.8K -100% Sep 18, 2024
Alicia Secor Director $0 Sep 18, 2024
Cynthia Louise Flowers Director $0 Sep 18, 2024
Norman Sharpless Director $0 Sep 18, 2024
W. Umstead John Chief Financial Officer $0 -$62.4K -100% Sep 18, 2024

Recent Insider Transactions by Companies or Individuals for G1 Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.